Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m
Cabazitaxel
Castration-resistant prostate cancer
Japan
Post-marketing surveillance
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
13 Jul 2020
13 Jul 2020
Historique:
received:
12
03
2020
accepted:
02
07
2020
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
28
1
2021
Statut:
epublish
Résumé
The recommended starting dose of cabazitaxel for castration-resistant prostate cancer (CRPC) is 25 mg/m We compared the safety and efficacy of cabazitaxel between patients who received cabazitaxel at starting doses of 25 and 20 mg/m The C20 and C25 groups comprised 190 and 159 patients without matching and 112 patients per group after matching. In unmatched patients, any-grade (C25 vs C20: 89.3% vs 78.4%, Fisher's p < 0.01) and grade ≥ 3 (81.1% vs 61.1%) ADRs were more frequent in the C25 group. Neutropenia (any grade: 61.6% vs 54.2%; grade ≥ 3: 55.3% vs 42.6%) and febrile neutropenia (grade ≥ 3: 30.2% vs 14.7%) were more frequent in the C25 group. In matched patients, the PSA response rate (reduction in PSA ≥30% from a baseline ≥5 ng/mL) was 26.4 and 32.0% in the C20 and C25 groups, respectively, median OS was 291 days (95% CI 230-not reached) versus not reached (hazard ratio 0.73, 95% CI 0.50-1.08), and TTF favored C25 (hazard ratio 0.75, 95% CI 0.57-0.99). Clinicians should consider the patient's risk of clinically significant ADRs and prophylactic granulocyte colony stimulating factor when selecting the starting dose of cabazitaxel for CRPC. Some patients at high risk of ADRs or unfit patients may benefit from a lower starting dose of 20 mg/m Not applicable.
Sections du résumé
BACKGROUND
BACKGROUND
The recommended starting dose of cabazitaxel for castration-resistant prostate cancer (CRPC) is 25 mg/m
METHODS
METHODS
We compared the safety and efficacy of cabazitaxel between patients who received cabazitaxel at starting doses of 25 and 20 mg/m
RESULTS
RESULTS
The C20 and C25 groups comprised 190 and 159 patients without matching and 112 patients per group after matching. In unmatched patients, any-grade (C25 vs C20: 89.3% vs 78.4%, Fisher's p < 0.01) and grade ≥ 3 (81.1% vs 61.1%) ADRs were more frequent in the C25 group. Neutropenia (any grade: 61.6% vs 54.2%; grade ≥ 3: 55.3% vs 42.6%) and febrile neutropenia (grade ≥ 3: 30.2% vs 14.7%) were more frequent in the C25 group. In matched patients, the PSA response rate (reduction in PSA ≥30% from a baseline ≥5 ng/mL) was 26.4 and 32.0% in the C20 and C25 groups, respectively, median OS was 291 days (95% CI 230-not reached) versus not reached (hazard ratio 0.73, 95% CI 0.50-1.08), and TTF favored C25 (hazard ratio 0.75, 95% CI 0.57-0.99).
CONCLUSIONS
CONCLUSIONS
Clinicians should consider the patient's risk of clinically significant ADRs and prophylactic granulocyte colony stimulating factor when selecting the starting dose of cabazitaxel for CRPC. Some patients at high risk of ADRs or unfit patients may benefit from a lower starting dose of 20 mg/m
TRIAL REGISTRATION
BACKGROUND
Not applicable.
Identifiants
pubmed: 32660451
doi: 10.1186/s12885-020-07131-6
pii: 10.1186/s12885-020-07131-6
pmc: PMC7359263
doi:
Substances chimiques
Taxoids
0
cabazitaxel
51F690397J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
649Références
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Eur J Cancer. 2016 Mar;56:93-100
pubmed: 26829012
Cancer Chemother Pharmacol. 2014 Apr;73(4):703-10
pubmed: 24488323
Jpn J Clin Oncol. 2019 Dec 27;49(12):1157-1163
pubmed: 31361807
Cancers (Basel). 2020 Apr 17;12(4):
pubmed: 32316580
Int J Clin Oncol. 2015 Oct;20(5):1026-34
pubmed: 25809824
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Ann Oncol. 2008 Sep;19(9):1547-52
pubmed: 18436520
Ann Oncol. 2013 Dec;24(12):2972-7
pubmed: 24126362
Front Oncol. 2016 Jan 11;5:304
pubmed: 26793621
BMC Cancer. 2013 Oct 07;13:460
pubmed: 24099585
Int J Urol. 2016 Feb;23(2):114-21
pubmed: 26311471
Future Oncol. 2014 May;10(6):975-83
pubmed: 24295376
J Clin Oncol. 2017 Oct 1;35(28):3198-3206
pubmed: 28809610
Int J Urol. 2017 Aug;24(8):566-572
pubmed: 28577511
Int J Urol. 2018 Jun;25(6):524-531
pubmed: 29740894
Int J Urol. 2017 Sep;24(9):648-666
pubmed: 28667698
Clin Cancer Res. 2009 Jan 15;15(2):723-30
pubmed: 19147780